| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2016-03-14 | merestinib (LY2801653) | biliary tract cancer | 2 | Eli Lilly (USA - IN) | Cancer - Oncology |
| 2016-03-14 | SYL1001 (tivanisiran) | eye discomfort associated with dry eye syndrome | 2 | Sylentis (Spain) | Ophtalmological diseases |
| 2016-03-14 | Epidiolex® (cannabidiol (2-[(1R,6R)-3-Methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1,3-benzenediol) | Dravet syndrome | 3 | GW Pharmaceuticals (UK) | Rare diseases |
| 2016-03-14 | ANAVEX 3-71 - 1-(2,8-Dimethyl-1-thia-3,8-diazaspiro[4.5]dec-3-yl)-3-(1H-indol-3-yl)propan-1-one | Alzheimer's disease | preclinical | Anavex Life Sciences (USA - NY) | Neurodegenerative diseases |
| 2016-03-14 | BioChaperone Lispro | type 1 diabetes mellitus | 1b | Adocia (France) Eli Lilly (USA - IN) | Metabolic diseases |
| 2016-03-11 | pamrevlumab (FG-3019) | idiopathic pulmonary fibrosis | 2 | FibroGen (USA - CA) | Lung diseases - Respiratory diseases - Rare diseases |
| 2016-03-11 | GDC-0310 | pain | 1 | Genentech, a member of Roche Group (USA - CA - Switzerland) | CNS diseases - Neurological diseases |
| 2016-03-11 | GDC-0276 | pain | 1 | Genentech, a member of Roche Group (USA - CA - Switzerland) | CNS diseases - Neurological diseases |
| 2016-03-10 | ANAVEX2-73 (tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride) | Alzheimer's diseased | 2 | Anavex Life Sciences (USA - NY) | Neurodegenerative diseases |
| 2016-03-10 | elafibranor - GFT505 | NASH (non-alcoholic steatohepatitis) | 3 | Genfit (France) | Metabolic diseases - Liver diseases |
| 2016-03-09 | Cresemba® (isavuconazole) | invasive fungal disease caused by Aspergillus species or other filamentous fungi | 3 | Basilea Pharmaceutica (Switzerland) Astellas Pharma (Japan) | Infectious diseases |
| 2016-03-08 | ofatumumab | pemphigus vulgaris | 3 | GSK (UK) | Autoimmune diseases - Dermatological diseases |
| 2016-03-08 | RHB-105 | Helicobacter pylori Infection | 3 | Redhill Biopharma (Israel) | Infectious diseases |
| 2016-03-07 | Rintega® (rindopepimut) | EGFRvIII positive glioblastoma |
3 | Celldex Therapeutics (USA - NJ) | Cancer - Oncology - Rare diseases |
| 2016-03-07 | ixekizumab | moderate-to-severe plaque psoriasis | 3 | Eli Lilly (USA -IN) | Autoimmune diseases - Dermatological diseases |
| 2016-03-07 | ARC-F12 | hereditary angioedema, thrombosis | preclinical | Arrowhead Research Corporation (USA - CA) | Rare diseases - Genetic diseases - Hematological diseases |
| 2016-03-07 | VL-2397 (cyclo{-Asn-Leu-d-Phe-Al[(N5-acetyl-N5-hydroxy-Orn)-(N5-acetyl-N5-hydroxy-Orn)-(N5-hydroxy-Orn)]-} . Al(III)) | invasive aspergillosis | 1 | Vical (USA - CA) | Infectious diseases |
| 2016-03-06 | Viaskin® Peanut | peanut allergy | 2b | DBV Technologies (France) | Allergic diseases - Immunological diseases |
| 2016-03-06 | Advair® Diskus® (salmeterol and fluticasone propionate) | asthma | 4 | GSK (UK) | Allergic diseases - Inflammatory diseases - Respiratory diseases |
| 2016-03-05 | mepolizumab | eosinophilic asthma | 3 | GSK (UK) | Allergic diseases - Inflammatory diseases - Respiratory diseases |
